In The Rush To Emerging Markets, Could Public Health Be The Winner?

Originally Published in The Metropolitan Corporate Counsel, March 2012.

What is the crashing noise so many pharmaceutical companies are hearing these days? Some say it is the sound of key products going over the “patent cliff.”

The press has focused recently on the number of blockbuster drugs that are coming off or have come off patent. The news has been big as the list is an impressive one – Plavix®, Lipitor®, Seroquel®, Actos®, Enbrel®, Singulair®, Levaquin®, Zyprexa®, Concerta® and Protonix®, just to name a few.With billions of dollars of revenue at stake, pharmaceutical companies have been considering for years how best to protect and build their businesses in light of this monumental change in the pharma landscape. It has become clear that looking abroad may be one of the best answers.

Please see full article below for more information.

LOADING PDF: If there are any problems, click here to download the file.

Published In: Administrative Agency Updates, General Business Updates, Health Updates, International Trade Updates, Science, Computers & Technology Updates

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Sheppard Mullin Richter & Hampton LLP | Attorney Advertising

Don't miss a thing! Build a custom news brief:

Read fresh new writing on compliance, cybersecurity, Dodd-Frank, whistleblowers, social media, hiring & firing, patent reform, the NLRB, Obamacare, the SEC…

…or whatever matters the most to you. Follow authors, firms, and topics on JD Supra.

Create your news brief now - it's free and easy »